Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Morphosys AG receives additional patents on novel antibody platform Ylanthia in the U.S. and first patent in China
Morphosys AG:Announces that the U.S. Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the company's latest antibody platform Ylanthia.
Latest Developments for Morphosys AG
Latest Key Developments in Biotechnology
- Immunomedics announces european orphan drug designation for Isactuzumab Govitecan for Pancreatic Cancer Treatment
- Matinas BioPharma Holdings Inc submits Investigational New Drug Application for Lead Product Candidate MAT9001 for treatment of severe hypertriglyceridemia
- Pharmacyclics Inc files supplemental new drug application for IMBRUVICA for Waldenstrom's Macroglobulinemia
- BBB Therapeutics BV appoints Jan van Heek as Chairman
- Share this
- Digg this